- Home
- GLMD vs NVVE Comparison
GLMD vs NVVE Comparison
Compare GLMD & NVVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLMD
- NVVE
- Stock Information
- Founded
- GLMD 2000
- NVVE 1996
- Country
- GLMD Israel
- NVVE United States
- Employees
- GLMD N/A
- NVVE N/A
- Industry
- GLMD Biotechnology: Pharmaceutical Preparations
- NVVE Oil Refining/Marketing
- Sector
- GLMD Health Care
- NVVE Energy
- Exchange
- GLMD Nasdaq
- NVVE Nasdaq
- Market Cap
- GLMD 4.5M
- NVVE 3.7M
- IPO Year
- GLMD 2014
- NVVE N/A
- Fundamental
- Price
- GLMD $1.46
- NVVE $1.13
- Analyst Decision
- GLMD
- NVVE
- Analyst Count
- GLMD 0
- NVVE 0
- Target Price
- GLMD N/A
- NVVE N/A
- AVG Volume (30 Days)
- GLMD 2.6M
- NVVE 178.6K
- Earning Date
- GLMD 05-29-2025
- NVVE 03-31-2025
- Dividend Yield
- GLMD N/A
- NVVE N/A
- EPS Growth
- GLMD N/A
- NVVE N/A
- EPS
- GLMD N/A
- NVVE N/A
- Revenue
- GLMD N/A
- NVVE $5,286,229.00
- Revenue This Year
- GLMD N/A
- NVVE $200.61
- Revenue Next Year
- GLMD N/A
- NVVE $109.43
- P/E Ratio
- GLMD N/A
- NVVE N/A
- Revenue Growth
- GLMD N/A
- NVVE N/A
- 52 Week Low
- GLMD $1.33
- NVVE $1.00
- 52 Week High
- GLMD $23.80
- NVVE $17.30
- Technical
- Relative Strength Index (RSI)
- GLMD 33.38
- NVVE 29.12
- Support Level
- GLMD $1.33
- NVVE $1.53
- Resistance Level
- GLMD $1.55
- NVVE $1.75
- Average True Range (ATR)
- GLMD 0.33
- NVVE 0.15
- MACD
- GLMD -0.04
- NVVE -0.01
- Stochastic Oscillator
- GLMD 5.90
- NVVE 17.33
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.
About NVVE Nuvve Holding Corp.
Nuvve Holding Corp is accelerating the electrification of transportation through its proprietary vehicle-to-grid (V2G) technology. It helps to support the integration of renewable energy sources, including solar and wind. Its Grid Integrated Vehicle (GIV) platform is refueling the next generation of electric vehicle fleets through bidirectional charging solutions. It has a geographic presence in the United States, the United Kingdom, and Denmark, of which it generates the majority of its revenue in the United States.